Hot Topics in Diabetes and Endocrinology for Primary Care

Sherman Oaks, CA US
April 7, 2018

Welcome, and thank you for attending the California Chapter of the American Association of Clinical Endocrinologists Hot Topics in Diabetes and Endocrinology for Primary Care Program in Sherman Oaks, CA. 

The California Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease. 

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities. 

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Family Practice, Internal Medicine Physicians, Nurse Practitioners, Physician Assistants and other health care professionals interested in the treatment of diabetes and other common endocrine diseases living in and around Sherman Oaks, CA.

Learning Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and current healthcare practices.
  2. How to implement the 2018 AACE Diabetes Algorithm into your practice
  3. Evaluating options with focus on incorporating SGLT2 Inhibitors and GLP-1ra's into therapy
    • Case scenario requiring addition of SGLT2i
    • Case scenario requiring GLP1ra
  4. Recognize when advanced Beta Cell failure is present and basal insulin is necessary
  5. Know when the newer basal insulin formulations are indicated and how to use these with other agents such as GLP-1 agonists
    • Case scenario requiring insulin initiation
    • Case scenario requiring insulin or additional agent intensification
  6. Incorporate the newest methods to collect and interpret blood glucose data in your practice
  7. Identify key components in evaluating the ambulatory glucose profile in order to minimize glucose variability and hypoglycemia of patients with diabetes
    • Case scenario with marked hypo and hyper-glycemia with a normal A1C
    • Case scenario differentiating Somogi phenomenon with Dawn phenomenon
    • Case scenario of a patient on MDI regimen who is not performing SBGM often enough
  8. Discuss current DM medications with proven CV risk reduction independent of glucose lowering
  9. Is time to look beyond glycemic control?
    • Case scenario with Diabetic patient s/p MI who needs additional therapy (may be complicated by renal insufficiency)
    • Case scenario with Diabetic patient s/p Stroke and history of compensated CHF and normal renal function
  10. Introduce the New AACE Lipid Guidelines
  11. Incorporate new agents to lower LDL cholesterol into a treatment paradigm
    • Case scenario with Statin Intolerant patient
    • Case study with patient who has Secondary Hyperlipidemia
    • Case scenario with patient who has Heterozygous FHH
    • Case scenario for Extremely High Risk patient
  12. Identify key components of thyroid function studies in different clinical situations
  13. Understand the values and pitfalls of Thyroid Ultrasound and thyroid Scan
    • Case scenario with Patient in Pregnancy
    • Case scenario with Patient with Subclinical Hypothyroidism
    • Case scenario with Subacute Thyroiditis
    • Case scenario with Hyperthyroidism
    • Case scenario with an Incidental Thyroid Nodule
  14. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 4.50 AMA
  • 4.50 Attendance
Course opens: 
04/07/2018
Course expires: 
04/07/2019
Event starts: 
04/07/2018 - 7:00am
Event ends: 
04/07/2018 - 12:45pm
Cost:
$0.00

Program Agenda

* Please click on the presentation title to view available materials.

Saturday, April 7, 2018

7:00 – 7:45 AMBreakfast / Registration
7:45 – 8:00 AMWelcome & Pre-Meeting Assessment

Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and current healthcare practices.
8:00 – 8:30 AMAACE Diabetes Algorithm-with Focus on SGLT2 Inhibitors
and GLP-1 Therapies

Yehuda Handelsman, MD, FACP, FNLA, MACE

Objectives

  1. How to implement the 2018 AACE Diabetes Algorithm into your practice
  2. Evaluating options with focus on incorporating SGLT2 Inhibitors and GLP-1ra's into therapy
    • Case scenario requiring addition of SGLT2i
    • Case scenario requiring GLP1ra
8:30 – 9:00 AMInsulin Initiation and Intensification with Focus on 
Hypoglycemia Reduction

Herbert Rettinger, MD, FACE

Objectives

  1. Recognize when advanced Beta Cell failure is present and basal insulin is necessary
  2. Know when the newer basal insulin formulations are indicated and how to use these with other agents such as GLP-1 agonists
    • Case scenario requiring insulin initiation
    • Case scenario requiring insulin or additional agent intensification
9:00 – 9:30 AMIncorporating CGM into Clinical Decision Making
Etie Moghissi, MD, FACP, FACE

Objectives

  1. Incorporate the newest methods to collect and interpret blood glucose data in your practice
  2. Identify key components in evaluating the ambulatory glucose profile in order to minimize glucose variability and hypoglycemia of patients with diabetes
    • Case scenario with marked hypo and hyper-glycemia with a normal A1C
    • Case scenario differentiating Somogi phenomenon with Dawn phenomenon
    • Case scenario of a patient on MDI regimen who is not performing SBGM often enough
9:30 – 10:00 AMCardiovascular Outcome Studies, Is It Time for Paradigm Shift?
Jennifer Han, MD, FACE

Objectives

  1. Discuss current DM medications with proven CV risk reduction independent of glucose lowering
  2. Is time to look beyond glycemic control?
    • Case scenario with Diabetic patient s/p MI who needs additional therapy (may be complicated by renal insufficiency)
    • Case scenario with Diabetic patient s/p Stroke and history of compensated CHF and normal renal function
10:00 – 10:15 AMPanel Discussion
10:15 – 10:45 AMBreak
10:45 – 11:15 AMManagement of Hyperlipidemia Beyond Statins
Chris Guerin, MD, FACE

Objectives

  1. Introduce the New AACE Lipid Guidelines
  2. Incorporate new agents to lower LDL cholesterol into a treatment paradigm
    • Case scenario with Statin Intolerant patient
    • Case study with patient who has Secondary Hyperlipidemia
    • Case scenario with patient who has Heterozygous FHH
    • Case scenario for Extremely High Risk patient
11:15 – 11:45 AMThyroid Conundrums
Dianne Cheung, MD, FACE

Objectives

  1. Identify key components of thyroid function studies in different clinical situations
  2. Understand the values and pitfalls of Thyroid Ultrasound and thyroid Scan
    • Case scenario with Patient in Pregnancy
    • Case scenario with Patient with Subclinical Hypothyroidism
    • Case scenario with Subacute Thyroiditis
    • Case scenario with Hyperthyroidism
    • Case scenario with an Incidental Thyroid Nodule
11:45 – 12:15 PMPanel Discussion
12:15 – 12:45 PMPost Meeting Assessment

Objectives

  1. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
12:45 PMAdjourn
Courtyard By Marriott
15433 Ventura Boulevard
Sherman Oaks, CA 91403
United States

Dianne S. Cheung, MD, MPH, FACE
Assistant Clinical Professor
University of California, Los Angeles
Department of Medicine
Division of Endocrinology, Diabetes, and Hypertension
Los Angeles, CA

*Chris K. Guerin, MD, FACE
Assistant Clinical Professor of Medicine
University of California, San Diego
Oceanside, CA

Jennifer Han, MD
Assistant Clinical Professor
UCLA
Division of Endocrinology, Diabetes & Hypertension
Torrance, CA

Yehuda Handelsman, MD, FACP, FNLA, MACE
Medical Director & Principal Investigator, Metabolic Institute of America
Past President, ACE & AACE
Tarzana, CA

*Etie Moghissi, MD, FACP, FACE
Clinical Associate Professor
University of California Los Angeles
Marina del Rey, CA

Herbert I. Rettinger, MD, FACE
Past President, CA-AACE
Clinical Professor of Medicine/Endocrinology
University of California, Irvine, Volunteer Faculty 1977-2015
President, Endocrinology Medical Group of Orange County, Inc.
Orange County, CA

*Indicates both a member of the Program Committee and faculty.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the California Chapter of AACE. AACE is accredited by the ACCME to provide continuing medical education for physicians. 

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 4.50 AMA
  • 4.50 Attendance

Accreditation Period

Course opens: 
04/07/2018
Course expires: 
04/07/2019

Price

Cost:
$0.00
Please login or register to take this course.